Latest News
Web Date: August 9, 2017

GSK to end neuroscience R&D in China

Shanghai was once the hub of the company’s neuroscience research effort
Department: Business
Keywords: drug discovery, GlaxoSmithKline, China, R&D, fraud, bribery

It wasn’t long ago that GlaxoSmithKline’s Shanghai lab led the firm’s research efforts in neurological diseases including Parkinson’s, multiple sclerosis, and Alzheimer’s. Now, after years of setbacks in China, the company is ending neuroscience R&D in Shanghai.

“Following a portfolio review and prioritization, we have decided to close our neuroscience R&D center in Shanghai and move key programs to our global R&D hub in Upper Providence [Pa.] in the U.S., where they will benefit from . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society